amiodarone has been researched along with DDPAC in 1 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alberici, A | 1 |
| Archetti, S | 1 |
| Pilotto, A | 1 |
| Premi, E | 1 |
| Cosseddu, M | 1 |
| Bianchetti, A | 1 |
| Semeraro, F | 1 |
| Salvetti, M | 1 |
| Muiesan, ML | 1 |
| Padovani, A | 1 |
| Borroni, B | 1 |
1 trial available for amiodarone and DDPAC
| Article | Year |
|---|---|
Results from a pilot study on amiodarone administration in monogenic frontotemporal dementia with granulin mutation.
Topics: Aged; Amiodarone; Antacids; DNA Mutational Analysis; Female; Frontotemporal Dementia; Humans; Interc | 2014 |